Vitamin K Antagonists Predispose to Calciphylaxis in Patients with End-Stage Renal Disease

Nephron

Volumn 129, Issue 3, 2015, Pages 197-201

  Galloway, Peter A G ^a   El Damanawi, Ragada ^a   Bardsley, Victoria ^c   Pritchard, Nicholas R ^b   Fry, Andrew C ^b   Ojha, Sanjay K ^b   Hiemstra, Thomas F ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Division of Renal Medicine   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Arteriolopathy; Calcific; Calciphylaxis; Dialysis; Uremic; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; AGED; AMPUTATION STUMP; ANTAGONISTS AND INHIBITORS; ARTERIOLE; CALCIPHYLAXIS; CASE REPORT; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMPLICATION; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; VENOUS THROMBOSIS;

ADULT; AGED; AMPUTATION STUMPS; ANTICOAGULANTS; ARTERIOLES; CALCIPHYLAXIS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; VENOUS THROMBOSIS; VITAMIN K;

EID: 84944037160     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000371449     Document Type: Article

References (20)

1. Brandenburg VM, Cozzolino M, Ketteler M: Calciphylaxis: a still unmet challenge. J Nephrol 2011; 24: 142-148.
2. Mazhar AR, Johnson RJ, Gillen D, et al: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324-332.
3. Lal G, Nowell AG, Liao J, Sugg SL, Weigel RJ, Howe JR: Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery 2009; 146: 1028-1034.
4. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR: Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56: 569-579.
5. Nigwekar SU, Wolf M, Sterns RH, Hix JK: Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3: 1139-1143.
6. Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggert W, Turchin A, et al: Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med 2014; 29(suppl 3):S724-S731.
7. Shanahan CM: Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol 2013; 9: 661-670.
8. Weenig RH: Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 2008; 58: 458-471.
9. Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, et al: Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22: 387-395.
10. Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, et al: Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant 2014; 29: 1633-1638.
11. Beazley KE, Eghtesad S, Nurminskaya MV: Quercetin attenuates warfarin-induced vascular calcification in vitro independently from matrix Gla protein. J Biol Chem 2013; 288: 2632-2640.
12. Rennenberg RJ, van Varik BJ, Schurgers LJ, et al: Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010; 115: 5121-5123.
13. Asobie N, Wong E, Cook MG: Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 2008; 33: 342-344.
14. Salmhofer H, Franzen M, Hitzl W, Koller J, Kreymann B, Fend F, et al: Multi-modal treatment of calciphylaxis with sodium-thiosulfate, cinacalcet and sevelamer including longterm data. Kidney Blood Press Res 2013; 37: 346-359.
15. Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, et al: Statin use and calcific uremic arteriolopathy: a matched casecontrol study. Am J Nephrol 2013; 37: 325-332.
16. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210-2217.
17. Woolf B: On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
18. Crotty R, Nazarian RM, Song PI, Van Cott EM: Heparin, warfarin, or calciphylaxis? Am J Hematol 2014; 89: 785-786.
19. Shah M, Avgil Tsadok M, Jackevicius CA, et al: Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129: 1196-1203.
20. Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997; 122: 1083-1089; discussion 1089-1090.